News
MYGN
5.54
+0.18%
0.01
BillionToOne Faces Short Report Alleging Kickbacks, Flawed Diagnostic Tests
Benzinga · 1d ago
Diagnostic stocks safe from proposed crackdown on Medicare fraud
Seeking Alpha · 2d ago
Myriad Genetics expands collaboration with SRL in Japan
TipRanks · 2d ago
Myriad Genetics Expands Collaboration With SRL To Enable Local Japanese Testing For Its BRACAnalysis Diagnostic System
Benzinga · 2d ago
Weekly Report: what happened at MYGN last week (1109-1113)?
Weekly Report · 3d ago
Myriad Genetics Earnings Call Signals Strategic Shift and Recovery
TipRanks · 5d ago
Myriad Genetics Is Maintained at Equal-Weight by Stephens & Co.
Dow Jones · 11/12 13:48
Myriad Genetics Price Target Raised to $6.00/Share From $3.00 by Stephens & Co.
Dow Jones · 11/12 13:48
Stephens & Co. Maintains Equal-Weight on Myriad Genetics, Raises Price Target to $6
Benzinga · 11/12 13:38
Myriad Genetics price target raised to $6 from $3 at Stephens
TipRanks · 11/12 11:41
AVAX One brings total convertible debt balance to zero
Seeking Alpha · 11/10 21:45
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Definitive Healthcare Corp (DH) and Myriad Genetics (MYGN)
TipRanks · 11/10 11:50
Myriad Genetics Consensus Price Target Increased by 21.17% to $5.55
NASDAQ · 11/10 00:19
Myriad Genetics, Inc. Approves Retention Option Awards for Executive Officers on November 6, 2026
NASDAQ · 11/09 22:41
Myriad Genetics Grants Retention Stock Options to Executives
TipRanks · 11/09 22:28
Weekly Report: what happened at MYGN last week (1102-1106)?
Weekly Report · 11/09 09:14
Regulatory Hurdles Put Myriad Genetics’ $210 Million Prenatal Health Sale to LabCorp at Risk
TipRanks · 11/08 06:00
Myriad Genetics Raises FY26 Revenue Outlook Midpoint; Agrees To Sell Prenatal Health Business
NASDAQ · 11/06 10:39
Myriad Genetics, Inc. Detects Unauthorized IT Network Access on November 2, 2026
NASDAQ · 11/06 04:48
Analysts Offer Insights on Healthcare Companies: Agios Pharma (AGIO), Myriad Genetics (MYGN) and Acadia Healthcare (ACHC)
TipRanks · 11/05 22:40
More
Webull provides a variety of real-time MYGN stock news. You can receive the latest news about Myriad Genetics through multiple platforms. This information may help you make smarter investment decisions.
About MYGN
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.